From lifesaving CRISPR therapies to groundbreaking cancer-targeting enzymes, gene editing is moving from lab experiments into real-world medicine. Scientists are not only curing rare diseases but also ...
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data ...
Researchers have developed a modified CRISPR gene-editing tool with potential to silence the extra chromosome causing Down ...
Researchers announced two major CRISPR breakthroughs: a method to boost production of virus-like particles for gene delivery, and a ThermoCas9 enzyme that can distinguish cancer cells from healthy ...
Researchers from Wageningen University & Research and Van Andel Institute used a variant of CRISPR, a gene-editing tool, to ...
Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene ...
National Institutes of Health (NIH) released the following: A National Institutes of Health (NIH)-funded research team has ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
We'll know more about the company's medium-term prospects by the end of the year.
Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors. Shares of Vertex, a biotech based ...